Neurobo Pharmaceuticals Inc
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has com… Read more
Neurobo Pharmaceuticals Inc (NRBO) - Total Liabilities
Latest total liabilities as of September 2024: $9.19 Million USD
Based on the latest financial reports, Neurobo Pharmaceuticals Inc (NRBO) has total liabilities worth $9.19 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neurobo Pharmaceuticals Inc - Total Liabilities Trend (2014–2023)
This chart illustrates how Neurobo Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Neurobo Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Neurobo Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stenocare AS
CO:STENO
|
Denmark | Dkr3.09 Million |
|
VIOL Co. Ltd
KQ:335890
|
Korea | ₩5.60 Billion |
|
Acrux Limited
PINK:ARUXF
|
USA | $6.20 Million |
|
Marvel Biosciences Corp.
PINK:MBCOF
|
USA | $4.33 Million |
|
Synertec Corporation Ltd
AU:SOP
|
Australia | AU$12.07 Million |
|
Digicontent Limited
NSE:DGCONTENT
|
India | ₹2.01 Billion |
|
NSX Ltd
AU:NSX
|
Australia | AU$6.20 Million |
|
XOX Technology Bhd
KLSE:0017
|
Malaysia | RM40.33 Million |
Liability Composition Analysis (2014–2023)
This chart breaks down Neurobo Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurobo Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurobo Pharmaceuticals Inc (2014–2023)
The table below shows the annual total liabilities of Neurobo Pharmaceuticals Inc from 2014 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $6.10 Million | -48.27% |
| 2022-12-31 | $11.78 Million | +435.15% |
| 2021-12-31 | $2.20 Million | -41.51% |
| 2020-12-31 | $3.77 Million | +73.02% |
| 2019-12-31 | $2.18 Million | -97.73% |
| 2018-12-31 | $96.03 Million | +536.98% |
| 2017-12-31 | $15.08 Million | +265.74% |
| 2016-12-31 | $4.12 Million | -75.58% |
| 2015-12-31 | $16.88 Million | +1820.36% |
| 2014-12-31 | $879.00K | -- |